Article Details
Retrieved on: 2024-11-18 13:10:27
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses Twist Bioscience's strong fiscal 2024 performance, highlighting revenue growth despite a slight decline in biopharma sales. It emphasizes Twist's advancements in synthetic biology and operational efficiency, improving adjusted EBITDA and gross margins.
Article found on: www.gurufocus.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here